Loading company…
Ovo Labs develops therapeutics intended to improve egg quality and IVF outcomes.
Ovo Labs is developing three therapeutics to address age-related declines in egg quality and fertility. Its preclinical programs target chromosome segregation errors in maturing eggs, with fertility clinics and healthcare providers as intended customers. Founded in 2025, the company is based in London, UK. In April 2025, it raised GBP 4 million in Seed funding co-led by Creator Fund and LocalGlobe, with participation from Blue Wire Capital and Ahren Innovation Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in